<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955552</url>
  </required_header>
  <id_info>
    <org_study_id>EF-093</org_study_id>
    <nct_id>NCT00955552</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee</brief_title>
  <acronym>Artico</acronym>
  <official_title>A Multi-center, Randomized, Double Blind, Comparative of Efficacy and Safety From Association of Capsules Glucosamine and Chondroitin Sulfate (Eurofarma) Versus Condroflex (Zodiac) to Patients Treatment With Osteoarthrosis of the Knee Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of glucosamine and chondroitin
      sulfate association in the treatment of patients with osteoarthrosis of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy and safety of the association of glucosamine sulphate 500
      mg/chondroitin sulphate 400 mg (Eurofarma) in the treatment of osteoarthritis, compared to
      Condroflex® (Zodiac) in same presentation and pharmaceutical form.

      Some eligibility criteria:

      Osteoarthritis of the knee confirmed by radiological examination; Visual analogue scale (VAS)
      &gt; 40 mm; Clinical diagnosis of pain and functional limitation
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">November 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy and safety of the association of glucosamine sulphate 500 mg/chondroitin sulphate 400 mg (Eurofarma) in the treatment of osteoarthritis, compared to Condroflex® (Zodiac) in same presentation and pharmaceutical form</measure>
    <time_frame>approximately 5 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Condroflex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucosamine/chondroitin sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine sulphate and chondroitin sulphate association</intervention_name>
    <description>glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal</description>
    <arm_group_label>Glucosamine/chondroitin sulphate</arm_group_label>
    <other_name>Artico Capsulas</other_name>
    <other_name>Glucosamine sulphate and Chondroitin sulphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Condroflex (Zodiac)</intervention_name>
    <description>oral capsule of glucosamine sulphate 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days</description>
    <arm_group_label>Condroflex</arm_group_label>
    <other_name>Condroflex</other_name>
    <other_name>glucosamine sulphate and chondroitin sulphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have to read and sign the approved the Informed Consent form prior to any
             participation in the study.

          -  Male or female Subjects, aged upper to 40 years.

          -  Osteoarthritis of the knee confirmed by radiological examination.

          -  Visual analogue scale (VAS) &gt; 40 mm.

          -  Kellgren and Lawrence grade 1 to 3.

          -  Clinical diagnosis of pain and functional limitation.

        Exclusion Criteria:

          -  History of significant trauma or surgery in the affected joint.

          -  Pregnant women, lactating or not using appropriate contraceptive method.

          -  History or presence of active rheumatic disease that may be responsible for secondary
             osteoarthritis.

          -  Severe inflammation of the joint confirmed by physical examination (excluding also
             erythrocyte sedimentation &lt;40mm/h and rheumatoid factor &lt;1:40).

          -  Body mass index &gt; 30.

          -  Hematologic abnormalities, liver, renal or metabolic functions which undermine the
             serious participation of the patient (at investigator's criteria).

          -  Systemic administration and/or intra-articular corticosteroids in the last 3 months.

          -  Have made use of glucosamine and/or chondroitin.

          -  Lequesne index of &gt; 12.

          -  Arthroplasty in the affected joint.

          -  Use of narcotic analgesics.

          -  Any condition that, in the opinion of the investigator, renders the patient unable to
             participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Branca B. Souza, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade da Santa Casa de Misericordia de Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marise L. Castro, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Medicina Avancada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristiano F. Zerbini, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Paulista de Investigacoes Clínicas Ltda.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose A. Mendonça, Phd/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituo de Pesquisa Clínica e Assistencia Medica de Campinas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carine M. Sanches, Coordinator</last_name>
    <phone>+55 11 5090 8727</phone>
    <email>carine.martins@eurofarma.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica e Assistencia Medica de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13073-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose A. Mendonca, Phd/MD</last_name>
      <phone>+55 19 3242 4077</phone>
      <email>mendoncaja@ig.com.br</email>
    </contact>
    <investigator>
      <last_name>Jose A. Mendonca, Phd/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01221-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Branca B. Souza, Phd/MD</last_name>
      <phone>+55 11 2176 7281</phone>
      <email>Branca_souza@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Branca B. Souza, Phd/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Paulista de Investigacoes Clinicas Ltda</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristiano F. Zerbini, Phd/MD</last_name>
      <phone>+55 11 2915 8325</phone>
      <email>criszerb@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Cristiano F. Zerbini, Phd/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Medicina Avancada</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05437-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marise L. Castro, PHd/MD</last_name>
      <phone>+55 11 3863 9156</phone>
      <email>marise.lazaretti@imabrasil.com.br</email>
    </contact>
    <investigator>
      <last_name>Marise L. Castro, Phd/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>March 3, 2010</last_update_submitted>
  <last_update_submitted_qc>March 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Carine Martins Sanches</name_title>
    <organization>Eurofarma Laboratorios Ltda</organization>
  </responsible_party>
  <keyword>osteoarthritis (OA)</keyword>
  <keyword>knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 22, 2017</submitted>
    <returned>November 3, 2017</returned>
    <submitted>March 15, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

